Biotech: Page 2
-
Startup Mariana raises $175M for radiopharmaceutical drug research
The Series B round makes Mariana one of the best funded private companies in a growing group of biotechs working on new radiopharmaceutical therapies.
By Delilah Alvarado • Sept. 7, 2023 -
Biogen, continuing executive revamp, finds a new research head
Jane Grogan, an industry veteran who worked at Genentech for over 15 years, will take over the role starting Oct. 2. She’ll fill a seat that's lacked a permanent replacement since the departure of Al Sandrock.
By Jacob Bell • Sept. 6, 2023 -
Explore the Trendline➔
luismmolina via Getty ImagesTrendlineThe expanding world of RNA therapies
Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.
By BioPharma Dive staff -
J&J sends blood pressure drug back to Idorsia
The decision is the latest in a series of setbacks for the Actelion spinout and ends a lucrative partnership that began in 2017.
By Kristin Jensen • Sept. 6, 2023 -
Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise
The Boston biotech has sold two experimental drugs — a liver disease medicine and a TYK2 inhibitor — to Gilead and Takeda respectively.
By Gwendolyn Wu • Sept. 6, 2023 -
Nestle gives up on peanut allergy treatment after sluggish sales
The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.
By Delilah Alvarado • Sept. 5, 2023 -
Star Therapeutics adds another $90M to grow its galaxy of drug startups
The hub-and-spoke biotech has raised more than $190 million in total to fund drug development for rare autoimmune and blood conditions.
By Gwendolyn Wu • Sept. 5, 2023 -
FDA documents hint at ‘uphill battle’ for broad approval of Sage’s depression drug
The newly posted documents show the agency had concerns about the side effects experienced by people with clinical depression who took Sage’s drug, Zurzuvae.
By Jacob Bell • Sept. 1, 2023 -
Sage, reeling from depression drug decision, to lay off 40% of workforce
Two founding executives are leaving Sage alongside a major restructuring announced weeks after the FDA approved the medicine, Zurzuvae, for much narrower use than the company had hoped.
By Kristin Jensen • Aug. 31, 2023 -
Intarcia, a former biotech unicorn, gets new life with startup deal
I2o Therapeutics, now led by former Intarcia head Kurt Graves, licensed the diabetes treatment Intarcia has spent more than a decade developing.
By Gwendolyn Wu • Aug. 30, 2023 -
Obesity drugs
Novo, continuing deal streak, buys another obesity drug startup
The acquisition of Embark Biotech, which Novo helped found, gives the company another prospect to add to its arsenal of weight-loss medicines.
By Jonathan Gardner • Aug. 30, 2023 -
FibroGen’s Duchenne drug fails second trial in latest study setback
The failure marks another Phase 3 miss for the drug, pamrevlumab, and follows a restructuring and CEO switch for the struggling biotech.
By Delilah Alvarado • Aug. 30, 2023 -
Epigenic joins wave of startups raising cash to edit the epigenome
The China-based company is one of at least four young biotechs in a competitive race to use CRISPR tools to alter gene expression without changing DNA.
By Kristin Jensen • Aug. 30, 2023 -
Apellis to lay off 25% of staff, trim research in major restructuring
The job cuts will affect about 225 employees, making it one of the largest single rounds of layoffs within the biotech sector this year.
By Ben Fidler • Aug. 29, 2023 -
Superluminal draws RA Capital, Nvidia as investors in GPCR drug hunt
GPCRs, a ubiquitous family of proteins that are prime drug targets, have drawn the interest of companies like Structure Therapeutics, Septerna and now Superluminal Medicines.
By Gwendolyn Wu • Aug. 28, 2023 -
Bayer reports positive early data for Parkinson’s cell therapy
The treatment, developed by a biotech Bayer acquired in 2019, appeared safe in a small trial and showed signs of an effect on disease progression.
By Jacob Bell • Aug. 28, 2023 -
Sponsored by Cognizant
Artificial intelligence: The prime mover in drug discovery
With its ability to process vast amounts of data and identify patterns, AI can significantly reduce the time and cost involved in developing new drugs.
Aug. 28, 2023 -
Emerging biotech
Neumora, a richly funded brain drug developer, readies for an IPO
Neumora’s filing, along with that of radiopharmaceutical startup RayzeBio last week, could be an important test of the biotech IPO market.
By Gwendolyn Wu • Aug. 25, 2023 -
Radiopharmaceutical drugmaker RayzeBio signals plans to go public
Biotech's IPO drought has endured into late August, but a small group of drugmakers are now in line ahead of a fall that analysts predict could be busier.
By Gwendolyn Wu • Aug. 25, 2023 -
Agenus to lay off 25% of staff, trim pipeline in cancer drug push
The job cuts are meant to preserve enough cash so the nearly three-decade-old company can potentially pursue its first drug approval next year.
By Delilah Alvarado • Aug. 23, 2023 -
J&J-backed startup raises another $150M for brain drug development
The funding for Rapport Therapeutics saw participation from a series of so-called crossover investors, many of which have pulled back from biotech startups in recent years.
By Jacob Bell • Aug. 23, 2023 -
Apellis finds faulty needles in probe of rare eye drug side effects
The company doesn’t know if the needles have caused retinal vasculitis in some people receiving its geographic atrophy drug Syfovre, but is no longer recommending their use.
By Kristin Jensen • Aug. 23, 2023 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
‘Project NextGen’ to spend $1.4B in search for better COVID drugs, vaccines
The funds going to Regeneron, clinical trial partners and other developers are the first major investments under a federal program announced in May.
By Ben Fidler • Aug. 22, 2023 -
Fulcrum rejoins sickle cell drug race as FDA lifts study hold
The biotech, which aims to develop an alternative to existing medicines and emerging gene-based treatments, will focus further testing on sicker patients.
By Ben Fidler • Aug. 22, 2023 -
Emerging biotech
Foundery, a new biotech venture firm, sets out to speed early immune drug research
Billing itself as both a scientific and investment partner, Foundery aims to provide drug development support to researchers working on new immunotherapies.
By Gwendolyn Wu • Aug. 22, 2023 -
FDA expands use of Neurocrine drug to Huntington’s patients
Analysts expect the approval of Ingrezza in Huntington’s patients with a movement disorder known as chorea to intensify a commercial battle between Neurocrine and Teva.
By Jacob Bell • Aug. 21, 2023